Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPA | P38571 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1678779 | 0.85 | — | — | |
| SCHEMBL17755696 | 0.80 | NR1H2 (0.32) | LIPA | |
| SCHEMBL6472476 | 0.79 | LIPA (0.40) | LIPAKMT2AMEN1PAX8CDC25B | |
| SCHEMBL10995818 | 0.78 | LIPA (0.34) | LIPAKMT2AMEN1PAX8CDC25B | |
| SCHEMBL4761987 | 0.78 | LIPA (0.38) | LIPAKMT2AMEN1PAX8CDC25B | |
| SCHEMBL26563234 | 0.77 | LIPA (0.47) | LIPAKMT2AMEN1PAX8CDC25B | |
| SCHEMBL1338880 | 0.75 | CYP1A2 (0.44) | — | |
| SCHEMBL1524887 | 0.75 | — | — | |
| SCHEMBL1153977 | 0.74 | SHBG (0.38) | — | |
| SCHEMBL1153349 | 0.74 | SHBG (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338626-A1 | METHODS FOR TREATING OR PREVENTING A VIRAL INFECTION OR INHIBITING VIRAL REPLICATION | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-11-04 | — | — | US | disclosed |
| WO-2021219495-A1 | METHODS FOR TREATING OR PREVENTING A VIRAL INFECTION OR INHIBITING VIRAL REPLICATION | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-11-04 | — | — | WO | disclosed |
| US-9000045-B2 | CETP activity inhibitors | JAPAN TOBACCO INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-20140243414-A1 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS | JAPAN TOBACCO INC. (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20130053417-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20110189210-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2011-08-04 | — | — | US | disclosed |
| EP-2319509-A1 | Method of Inhibiting remnant lipoprotein production | Japan Tobacco, Inc. (JP) | 2011-05-11 | — | — | EP | disclosed |
| EP-2316447-A1 | Method of inhibiting remnant lipoprotein production | Japan Tobacco, Inc. (JP) | 2011-05-04 | — | — | EP | disclosed |
| US-20100197736-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1710231-A1 | CETP activity inhibitors | Japan Tobacco, Inc. (JP) | 2006-10-11 | — | — | EP | disclosed |
| EP-1603553-A2 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS | JAPAN TOBACCO INC. (JP) | 2005-12-14 | — | — | EP | disclosed |
| US-20040229957-A1 | cholesterol ester transfer protein inhibitors, new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia | JAPAN TOBACCO INC. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-20040225018-A1 | administering S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate and a water-insoluble concentration-enhancing additive crospovidone, for treating or preventing a cardiovascular disorder in a mammal | JAPAN TOBACCO INC. (JP) | 2004-11-11 | — | — | US | disclosed |
| WO-2004082593-A2 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS | JAPAN TOBACCO INC. (JP) | 2004-09-30 | — | — | WO | disclosed |
| US-6753346-B2 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS | JAPAN TOBACCO INC. (JP) | 2004-06-22 | — | — | US | disclosed |
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | JAPAN TOBACCO, INC., A JAPAN CORPORATION | 2003-05-15 | — | — | US | disclosed |
| US-6426365-B1 | Anticholesterol agents; Cholesterol ester transfer protein (CETP); including dalcetrapib, S-(2-(((1-(2-ethylbutyl)cyclohexyl)carbonyl)amino) phenyl) 2-methylpropanethioate | JAPAN TOBACCO INC. (JP) | 2002-07-30 | — | — | US | disclosed |
| EP-1020439-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229957-A1 | cholesterol ester transfer protein inhibitors, new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia | CETP, MTTP, LCAT | LIPA 18/4885KMT2A 2700/4885MEN1 4682/4885 |
| US-20210338626-A1 | METHODS FOR TREATING OR PREVENTING A VIRAL INFECTION OR INHIBITING VIRAL REPLICATION | ACE, ACE2, REN | LIPA 281/4885KMT2A 886/4885MEN1 4536/4885 |
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | CETP, CES1, PON1 | LIPA 4/4885KMT2A 2748/4885MEN1 4510/4885 |
| US-20130053417-A1 | CETP ACTIVITY INHIBITORS | CETP, PCSK9, LCAT | LIPA 12/4885KMT2A 1505/4885MEN1 3545/4885 |
| US-20140243414-A1 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS | CETP, NPC1L1, LCAT | LIPA 8/4885KMT2A 3000/4885MEN1 4450/4885 |
| US-20110189210-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | CETP, PCSK9, LIPA | LIPA 3/4885KMT2A 3163/4885MEN1 3522/4885 |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | CETP, SI, LIPC | LIPA 9/4885KMT2A 2226/4885MEN1 2385/4885 |
| US-20100197736-A1 | CETP ACTIVITY INHIBITORS | CETP, MTTP, CES1 | LIPA 19/4885KMT2A 2825/4885MEN1 4714/4885 |
| US-20140364493-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | CETP, PCSK9, LIPA | LIPA 3/4885KMT2A 3163/4885MEN1 3522/4885 |
| US-20040225018-A1 | administering S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate and a water-insoluble concentration-enhancing additive crospovidone, for treating or preventing a cardiovascular disorder in a mammal | CETP, MTTP, PCTP | LIPA 52/4885KMT2A 2312/4885MEN1 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.